Allspring Global Investments
FDMT icon

Allspring Global Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Allspring Global Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27
Closed -$291 – 1986
2024
Q3 		$291 Buy
+27
New +$448 ﹤0.01% 2396
2024
Q2 		– Sell
-3,457
Closed -$110K – 2428
2024
Q1 		$110K Buy
3,457
+3,026
+702% +$77.2K ﹤0.01% 1824
2023
Q4 		$8.73K Sell
431
-92
-18% -$1.21K ﹤0.01% 2031
2023
Q3 		$6.66K Buy
+523
New +$8.75K ﹤0.01% 2656
2023
Q1 		– Sell
-12,758
Closed -$283K – 2822
2022
Q4 		$283K Sell
12,758
-8,190
-39% -$127K ﹤0.01% 1747
2022
Q3 		$168K Buy
+20,948
New +$190K ﹤0.01% 1877
2022
Q2 		– Sell
-7,806
Closed -$118K – 2762
2022
Q1 		$118K Sell
7,806
-905
-10% -$14.2K ﹤0.01% 2714
2021
Q4 		$191K Buy
+8,711
New +$214K ﹤0.01% 2643

Other funds holding FDMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Allspring Global Investments's FDMT Position: Q4 2024 in Review

Allspring Global Investments sold out of 4D Molecular Therapeutics (FDMT) in Q4 2024, closing a stake of 27 shares — an estimated $291 sold.

Allspring Global Investments first reported a position in FDMT in Q4 2021 and held it in 8 quarters. The position peaked at $283K in Q4 2022. 145 funds tracked by Wall St. Rank hold FDMT as of Q4 2024.

  • Allspring Global Investments reported no remaining 4D Molecular Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 27 4D Molecular Therapeutics shares in Q4 2024, an estimated $291.
  • Allspring Global Investments first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 8 quarters.
  • Allspring Global Investments's 4D Molecular Therapeutics position peaked at $283K in Q4 2022.
  • 145 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.